The U.S. infectious disease diagnostics market is expected to grow at a CAGR of 5.65% from 2025 to 2032, increasing from USD 10.14 billion in 2024 to USD 15.48 billion by 2032. This market expansion is fueled by the rising prevalence of infectious diseases, a growing selection of diagnostic tests, and the increasing adoption of point-of-care diagnostics. Innovation in disease detection and monitoring by key industry players is also driving growth, alongside rising investments in advanced disease model analysis and strategic initiatives by market leaders.
Overview of Infectious Disease Diagnostics
Infectious disease diagnostics involves identifying the underlying pathogen—whether bacteria, viruses, fungi, or parasites—responsible for a patient’s illness. Accurate diagnosis is crucial for effective treatment and is performed through laboratory tests (such as blood, urine, and tissue analysis) and imaging scans. Detection methods range from culturing and biochemical identification to genetic and antigenic analysis. Modern diagnostic approaches also utilize molecular technologies and immune response testing to improve accuracy, particularly in resource-limited settings.
However, market growth may be challenged by factors such as limited awareness of advanced diagnostic solutions, inconsistent regulatory guidelines, and low detection rates due to subpar lab conditions. In response, market participants are focusing on new product launches and business strategies to drive expansion.
In January 2025, Inflammatix, Inc. secured FDA approval for its TriVerity Test System, a next-generation molecular test designed for diagnosing acute infections and sepsis. This test assesses a patient’s immune response to differentiate between bacterial and viral infections while evaluating illness severity. The approval of such cutting-edge diagnostic tools is expected to strengthen market growth by enhancing diagnostic accuracy and instilling confidence in clinical evaluations.
Click – https://www.marketsandata.com/industry-reports/united-states-infectious-disease-diagnostics-market
Rising Prevalence of Infectious Diseases
The increasing incidence of infectious diseases has become a significant global concern, with past outbreaks like COVID-19, SARS, and swine flu highlighting the urgent need for rapid diagnostics. Factors contributing to the spread of infections include environmental changes, urbanization, increased travel, and antibiotic resistance.
The demand for diagnostic solutions correlates directly with infection rates, as timely detection is crucial for effective treatment and outbreak control. For example, according to WHO, tuberculosis (TB) remains a leading infectious disease, with CDC reporting a 15.6% rise in U.S. TB cases from 8,332 in 2022 to 9,633 in 2023. This surge underscores the need for more advanced diagnostic tools, boosting market growth.
Similarly, rising HIV infections in the U.S. have intensified the demand for point-of-care diagnostics (POCD). The government aims to cut new HIV cases from 32,800 in 2022 to 9,300 by 2025 and further to 3,000 by 2030. POCD plays a vital role in early disease detection and timely intervention, thereby accelerating the expansion of the U.S. diagnostic market.
To address this growing demand, companies and regulatory bodies are advancing diagnostic technologies. In April 2025, Cepheid Inc., a Danaher Corporation subsidiary, obtained WHO prequalification for its Xpert HIV-1 Qual XC test, designed for detecting HIV-1 in blood samples.
Diverse Range of Diagnostic Tests Enhancing Market Growth
The market benefits from a broad selection of diagnostic tests, including laboratory testing, rapid diagnostic kits, serological assays, and PCR-based techniques. These tests help detect antibodies, antigens, and microbial genetic material, enabling precise disease identification.
- Laboratory tests analyze bodily fluids such as blood, urine, and sputum using culturing, staining, and molecular identification techniques.
- Rapid diagnostic tests (RDTs) provide near-instant results to facilitate immediate clinical decision-making.
- Serological testing detects antibodies to determine prior exposure to infections.
- Polymerase Chain Reaction (PCR) testing identifies microbial DNA for highly accurate diagnoses.
This diverse range of diagnostic methods is expected to drive market growth further.
For instance, in December 2024, Delve Bio, Inc. launched Delve Detect, a metagenomic test designed to identify over 68,000 pathogens from cerebrospinal fluid (CSF) samples within 48 hours. This innovation significantly enhances diagnostic capacity, expanding the U.S. market by meeting the demand for rapid and precise testing solutions.
Dominance of Reagents, Kits, and Consumables Segment
The reagents, kits, and consumables segment currently holds the largest share of the U.S. infectious disease diagnostics market. This dominance is driven by recurring demand for consumables, advancements in molecular diagnostics, and the growing incidence of infectious diseases. The segment continues to benefit from repeat purchases, ensuring sustained growth.
For example, in December 2024, Panadea Diagnostics GmbH introduced innovative Fc-receptor-based ELISA kits for detecting IgG antibodies against Zika, Dengue, and West Nile viruses, along with an IgM kit for Dengue detection. These advancements reinforce the segment’s leading position by providing reliable, high-precision diagnostic solutions.
Future Market Trends (2025-2032)
Looking ahead, the U.S. infectious disease diagnostics market is expected to grow due to increasing regulatory approvals and product innovations. Agencies like BARDA have played a key role in supporting medical advancements, leading to 86 FDA-approved diagnostic solutions. Likewise, organizations such as the Infectious Diseases Society of America (IDSA) are advocating for regulatory incentives to spur research and development in diagnostics.
The FDA continues to authorize new diagnostic tools for infectious diseases, including influenza and respiratory syncytial virus, further fostering market expansion.
Report Scope
The report “United States Infectious Disease Diagnostics Market Assessment, Opportunities, and Forecast, 2018-2032” by Markets and Data offers an in-depth analysis of market dynamics, challenges, and growth opportunities. Covering key market players, segmental trends, and future projections, it provides a comprehensive overview of the evolving landscape of the U.S. infectious disease diagnostics industry.
Contact
Mr. Vivek Gupta5741 Cleveland street,Suite 120, VA beach, VA, USA 23462Tel: +1 (757) 343–3258Email: info@marketsandata.comWebsite: https://www.marketsandata.com
